Copper chelator induced efficient episodic memory recovery in a non-transgenic Alzheimer's mouse model

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Ceccom, Johnatan ^a   Coslédan, Frédéric ^b   Halley, Hélène ^a   Francès, Bernard ^a   Lassalle, Jean Michel ^a   Meunier, Bernard ^b,c  

^a Université Paul Sabatier   (France)

^b Palumed   (France)

^c LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

8 AMINOQUINOLINE DERIVATIVE; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; COPPER; MEMANTINE; PA 1637; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHELATION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DRUG SAFETY; DRUG STRUCTURE; EPISODIC MEMORY; EYE TOXICITY; MALE; MOUSE; NONHUMAN; TREATMENT DURATION;

ALZHEIMER DISEASE; AMINOQUINOLINES; AMYLOID BETA-PEPTIDES; ANIMALS; CHELATING AGENTS; COGNITION; COPPER; DISEASE MODELS, ANIMAL; INJECTIONS; MALE; MEMORY, EPISODIC; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; RECOVERY OF FUNCTION; TIME FACTORS;

EID: 84865189086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043105     Document Type: Article

References (42)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117.
2. Barnham KJ, Masters CL, Bush AI, (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3: 205-214.
3. Scott LE, Orvig C, (2009) Medicinal inorganic chemistry approaches to passivation and removal of aberrant metal ions in disease. Chem Rev 109: 4885-4910.
4. Perrone L, Mothes E, Vignes M, Mockel A, Figueroa C, et al. (2010) Copper transfer from Cu-Abeta to human serum albumin inhibits aggregation, radical production and reduces Abeta toxicity. Chembiochem 11: 110-118.
5. Sanokawa-Akakura R, Cao W, Allan K, Patel K, Ganesh A, et al. (2010) Control of Alzheimer's amyloid beta toxicity by the high molecular weight immunophilin FKBP52 and copper homeostasis in Drosophila. PLoS One 5: e8626.
6. Meloni G, Sonois V, Delaine T, Guilloreau L, Gillet A, et al. (2008) Metal swap between Zn7-metallothionein-3 and amyloid-beta-Cu protects against amyloid-beta toxicity. Nat Chem Biol 4: 366-372.
7. Sarell CJ, Wilkinson SR, Viles JH, (2010) Substoichiometric levels of Cu2+ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid-{beta} from Alzheimer disease. J Biol Chem 285: 41533-41540.
8. Kitazawa M, Cheng D, Laferla FM, (2009) Chronic copper exposure exacerbates both amyloid and tau pathology and selectively dysregulates cdk5 in a mouse model of AD. J Neurochem 108: 1550-1560.
9. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, et al. (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691.
10. Quinn JF, Crane S, Harris C, Wadsworth TL, (2009) Copper in Alzheimer's disease: too much or too little? Expert Rev Neurother 9: 631-637.
11. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59: 43-55.
12. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, et al. (2010) PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis 20: 509-516.
13. Boldron C, Van der Auwera I, Deraeve C, Gornitzka H, Wera S, et al. (2005) Preparation of cyclo-phen-type ligands: chelators of metal ions as potential therapeutic agents in the treatment of neurodegenerative diseases. Chembiochem 6: 1976-1980.
14. Deraeve C, Pitie M, Mazarguil H, Meunier B, (2007) Bis-8-hydroxyquinoline ligands as potential anti-Alzheimer agents. New J Chem 31: 193-195.
15. Deraeve C, Boldron C, Maraval A, Mazarguil H, Gornitzka H, et al. (2008) Preparation and study of new poly-8-hydroxyquinoline chelators for an anti-Alzheimer strategy. Chemistry 14: 682-696.
16. Deraeve C, Maraval A, Vendier L, Faugeroux V, Pitie M, et al. (2008) Preparation of new bis(8-aminoquinoline) ligands and comparison with bis(8-hydroxyquinoline) ligands on their ability to chelate CuII and ZnII. Eur J Inorg Chem 2008: 5622-5631.
17. Deraeve C, Pitie M, Boldron C, Meunier B (2005) Nouveaux dérivés polyquinoléines et leur utilisation thérapeutique. French Patent Application, August 4th, 2005, n° 0508351.
18. Sarell CJ, Syme CD, Rigby SE, Viles JH, (2009) Copper(II) binding to amyloid-beta fibrils of Alzheimer's disease reveals a picomolar affinity: stoichiometry and coordination geometry are independent of Abeta oligomeric form. Biochemistry 48: 4388-4402.
19. Feaga HA, Maduka RC, Foster MN, Szalai VA, (2011) Affinity of Cu+ for the copper-binding domain of the amyloid-beta peptide of Alzheimer's disease. Inorg Chem 50: 1614-1618.
20. Arbiser JL, Kraeft SK, van Leeuwen R, Hurwitz SJ, Selig M, et al. (1998) Clioquinol-zinc chelate: a candidate causative agent of subacute myelo-optic neuropathy. Mol Med 4: 665-670.
21. Quinn JF, Harris CJ, Cobb KE, Domes C, Ralle M, et al. (2010) A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 21: 903-914.
22. Adlard PA, Bica L, White AR, Nurjono M, Filiz G, et al. (2011) Metal ionophore treatment restores dendritic spine density and synaptic protein levels in a mouse model of Alzheimer's disease. PloS ONE 6(3): e17669.
23. Zahs KR, Ashe KH, (2010) 'Too much good news'- are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 33: 381-389.
24. Van Dam D, De Deyn PP, (2006) Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 5: 956-970.
25. Eisele YS, Bolmont C, Heikenwalder M, Langer F, Jacobson LH, et al. (2009) Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation. PNAS, 106, 12926-12931.
26. Yan JJ, Cho JY, Kim HS, Kim KL, Jung JS, et al. (2001) Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br J Pharmacol 133: 89-96.
27. Jhoo JH, Kim HC, (2004) Beta-amyloid (1-42) induced learning and memory deficits in mice: involvement of oxidative burdensin the hippocampus and cerebral cortex. Behav Brain res. 155,: 185-196.
28. Haas C, Selkoe DJ., (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Molec Cell Biol. 8,: 101-112.
29. Ohyagi Y, Asahara H, Chui DH, Tsuruta Y, Sakae N, et al. (2005) Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease. FASEB J 19: 255-257.
30. Ahmed M, Davis J, Aucoin D, Sato T, Ahuja S, et al. (2010) Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat Struct Mol Biol 17: 561-567.
31. Glabe CG, (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283: 29639-29643.
32. LeDoux JE, (1992) Brain mechanisms of emotion and emotional learning. Curr Opin Neurobiol 2: 191-197.
33. Fendt M, Fanselow MS, (1999) The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23: 743-760.
34. Daumas S, Halley H, Frances B, Lassalle JM, (2005) Encoding, consolidation, and retrieval of contextual memory: differential involvement of dorsal CA3 and CA1 hippocampal subregions. Learn Mem 12: 375-382.
35. Lipton SA, (2006) Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5: 160-170.
36. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G, (2002) Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 958: 210-221.
37. Tateishi J, (2000) Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 20 (suppl.): S20-S24.
38. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, et al. (2009) Increasing Cu bioavailability inhibits Abeta oligomers and tau phosphorylation. Proc Natl Acad Sci U S A 106: 381-386.
39. Squitti R, Salustri C, (2009) Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Curr Alzheimer Res 6: 476-487.
40. Franklin KBJ, Paxinos G (2001) The mouse brain in stereotaxic coordinates. Academic Press, San Diego.
41. Blanchard RJ, Blanchard DC, (1968) Limbic lesions and reflexive fighting. J Comp Physiol Psychol 66: 603-605.
42. Martin P, Bateson P (1988) Measuring Behaviour. An introductory guide. Cambridge University Press.